Biocon Foundation has been steadfast in its mission to empower underserved communities through innovative healthcare solutions, education, and sustainable development initiatives
YESINTEK is approved for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis
Dr. Prabhavathi brings over 14 years of unparalleled experience in pediatrics and a specialized focus on neurodevelopmental disorders
Richard A. Gonzalez to retire from the board of directors effective July 1, 2025
Biocon’s subsidiary Biocon Biologics Limited, which also participated independently in the assessment for the first time, reported an S&P Global ESG Score of 53
Successfully transformed the organization from a two-country operation focused on development and manufacturing to a fully integrated company with a strong commercial engine bringing us closer to patients in over 120 countries
Parents, teachers, and caregivers play a vital role in spotting early signs of schizophrenia
The segment has immense growth potential driven by the country's increasing healthcare needs, technological innovations, government support, and emerging market opportunities
Biocon Biologics is among the two pharmaceutical companies from India in the 93 companies featuring on the Asia IP Elite 2024 list
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
